Mark Knapp

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

André Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh et al. · Blood · 2019 · 134 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +12

Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma

Sven de Vos, André Goy, Shaker R. Dakhil et al. · Journal of Clinical Oncology · 2009 · 94 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Corey J. Langer, Mary W. Redman, James L. Wade et al. · Journal of Thoracic Oncology · 2019 · 87 citations

Medicine, Oncology, Pharmacology +10

Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study

Nathan Fowler, Loretta J. Nastoupil, Sven de Vos et al. · Blood · 2015 · 35 citations

Pharmacy, Hematology, Immunology +10